Prenetics reported that its IM8 health and longevity brand achieved a record $9.0 million in monthly revenue for October 2025, up 32% from September’s $6.8 million.
The brand’s annualized recurring revenue now stands at approximately $108 million, reaching the milestone 11 months after its commercial launch on November 18, 2024. This places IM8 among the fastest‑growing supplement brands worldwide.
The company also closed a $44 million equity offering on October 28, 2025, which strengthens its balance sheet and supports global expansion, new athlete partnerships, and broader market penetration.
Management highlighted that the revenue surge is driven by strong subscriber growth, an increase in average order value from $110 to $145 following the launch of Daily Ultimate Longevity, and improved retention metrics. The company expects monthly revenues to reach at least $10 million by December 2025 and projects FY 2026 revenue between $180 million and $200 million.
Prenetics’ broader portfolio continues to grow, with CircleDNA and Europa contributing $6.4 million in Q1 2024 revenue. The company also disclosed a Bitcoin treasury strategy, holding 378 BTC valued at roughly $46 million as of October 31, 2025.
While the rapid expansion presents opportunities, management noted potential challenges such as scaling production capacity, intensifying competition in the global consumer health market, and managing customer acquisition costs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.